Why Synergy Pharmaceuticals (SGYP) Stock Is Surging This Morning

NEW YORK (TheStreet) -- Shares of Synergy Pharmaceuticals Inc. (SGYP) are up 8.51% to $5.23 in pre-market trade after the company announced that its experimental constipation drug met the main goal of a mid-stage study in patients with a form of irritable bowel syndrome, Reuters reports.

The trial tested four doses of the drug in patients with irritable bowel syndrome with constipation, and the company said it selected a 3 mg dose to be tested in late-stage studies in the second half of the year.

Synergy said the drug was safe and well tolerated in the study, with no serious adverse events related to the treatment.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

SGYP Chart

SGYP data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months.Learn more.

If you liked this article you might like

Winning FDA Approval Isn't Always a Win

Will Allergan's Deal With Tribe Hold Up?

2 Small Biotechs Under $5 May Be Bargains

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

3 Biotech Stocks on Readers' Minds